Serum Institute Advances Dengue Candidate into Phase III Global Trials Following DNDi Licensing Agreement

A Phase III clinical trial for Serum Institute of India's dengue candidate is set to begin early next year across Brazil, Malaysia, and Thailand, placing tropical disease clinical supply chains under immediate operational scrutiny for contract manufacturers and QA leads supporting multi-regional studies.

The trial follows a licensing agreement between Serum Institute and DNDi (Drugs for Neglected Diseases initiative), a non-profit drug development organisation. The partnership structure positions DNDi as the clinical development driver, with Serum Institute supplying the investigational compound. For manufacturing and quality teams, the cross-continental trial footprint introduces parallel regulatory submissions across at least three distinct health authority jurisdictions, each with its own GMP inspection cadence and import licensing requirements.

Running concurrent sites in Southeast Asia and Latin America demands that clinical trial material (CTM) supply chains account for cold-chain integrity, country-specific labelling under local regulatory frameworks, and batch release timelines aligned to site activation schedules. Comparator sourcing and investigational medicinal product (IMP) documentation will need to satisfy both ICH E6(R3) Good Clinical Practice standards and the national requirements of Brazil's ANVISA, Malaysia's NPRA, and Thailand's FDA simultaneously.

For CDMOs engaged in tropical disease programs, the Serum Institute-DNDi model reflects a broader pattern: originator-nonprofit licensing arrangements that transfer clinical execution responsibility while retaining manufacturing at the originator site. Quality agreements, technology transfer protocols, and batch record harmonisation across geographies become critical GMP compliance checkpoints before first patient dosing.

The Phase III initiation timeline, targeting early 2027, gives supply chain and regulatory affairs teams a defined window to complete IND-equivalent filings, establish qualified person (QP) release frameworks for each country, and validate packaging lines for tropical climate distribution.

Source: Media4Growth via Indian Pharma Post, 7 July 2026.